Search 

AriVan Research LLC (AVR) is a specialized consulting firm that works closely with biopharmaceutical companies, diagnostic companies, medical device manufacturers, and other clients to support business development, commercialization and R&D activities.  Our expertise involves conducting in-depth primary research with KOLs, clinical investigators, healthcare company personnel, payers, and other industry sources to address important business- and scientific-related questions and issues.  A thorough analysis of secondary and/or audit data is often completed as well.  From there, our highly-experienced group of MBAs, MDs & PharmDs analyzes the information to provide rational and insightful recommendations.  

Avanir Pharmaceuticals, Inc. is a biotechnology company focused on acquiring, developing, and commercializing novel therapeutic products for the treatment of central nervous system disorders.  Our lead product, NUEDEXTA, is a dual sigma-1/NMDA receptor modulator and is the first and only FDA-approved treatment for pseudobulbar affect (PBA).  PBA is a condition affecting many patients with Alzheimer's / dementia, stroke, MS, Parkinson's, and other forms of neurological disease or injury and is characterized by uncontrolled episodes of crying or laughing.  

Avanir is commercializing NUEDEXTA in the United States through its specialty sales force calling primarily on neurology and psychiatry clinics as well as nursing homes.  Recent commercial milestones include over 10,000 Rx's during the month of August 2012 (up 9% relative to the prior month), which equates to a gross NUEDEXTA sales run-rate of over $65 million per year.

Avanir has a pending MAA for NUEDEXTA with the European regulatory authorities and is also conducting clinical trials in additional indications such as agitation in dementia, neuropathic pain in multiple sclerosis, and other areas where dual sigma-1/NMDA receptor targeted therapies can address unmet needs.